Skip to main content

Optimizing drug safety monitoring to enhance patient safety and achieve better health outcomes

Objective

"Medicines are one of the most common health interventions. Expenditure on pharmaceuticals range from 10–20 % of all health expenditure in rich countries & from 20–60 % in poor countries. Knowledge of appropriate & safe medicines has grown. But the incidence of medicines adverse effects remains high. In a UK study 6.5% of hospitals admissions were related to an adverse drug reaction (ADR). And as many as 10% of hospital admissions may result in death or disease due to errors, half of which may be avoidable. There are gaps in what we know. But even where there is sufficient knowledge, brokering of that knowledge is insufficient. There is a clear & present need to build a network of stakeholders in patient safety, to strengthen information & share the evidence towards actionable learning. The EC Work Programme for 2007–2008 relating to health calls for projects that ""advance the applications of evidence based medicine in Europe"". This proposal will respond to that call by strengthening what we know about medicines, sharing that knowledge, & putting that knowledge to use, to reduce patient deaths & adverse effects due to medicines. Specifically, building patient safety networking to: 1. support & strengthen consumer reporting of ADRs & adverse events 2. expand the role of national pharmacovigilance centres to prevent medicine-related adverse events 3. promote better & broader use of existing pharmacovigilance data for patient safety 4. develop additional methods of pharmacovigilance to complement data from spontaneous reporting systems. Achieving these objectives will help build the scientific basis needed for making informed policy decisions on disease prevention & therapy, & management of resources for health. In particular achieving these objectives will help to identify best clinical practice, to understand decision-making in clinical settings in primary & specialized care & to foster application of evidence-based medicine & patient empowerment."

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/adverse drug reactions
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug safety

Call for proposal

FP7-HEALTH-2007-B
See other projects for this call

Funding Scheme

CSA-CA - Coordination (or networking) actions

Coordinator

Stiftelsen WHO Collaborating Centre for International Drug Monitoring
Address
Bredgrand 7
S-75140 Uppsala
Sweden
Activity type
Research Organisations
EU contribution
€ 863 601
Administrative Contact
Birgitta Toreheim (Ms.)

Participants (10)

WORLD HEALTH ORGANIZATION
Switzerland
EU contribution
€ 663 496
Address
Avenue Appia 20
1211 Geneve
Activity type
Research Organisations
Administrative Contact
Kees De Joncheere (Dr.)
LAKEMEDELSVERKET
Sweden
EU contribution
€ 24 475
Address
Dag Hammarskjolds Vag 42
75103 Uppsala
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Anders Carlsten (Dr.)
STICHTING LAREB
Netherlands
EU contribution
€ 19 393
Address
Goudsbloemvallei 7
5237 MH S Hertogenbosch
Activity type
Research Organisations
Administrative Contact
Kees Van Grootheest (Dr.)
National Patient Safety Agency
United Kingdom
EU contribution
€ 26 455
Address
Maple Street 4-8
W1 T 5 HD London
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
David Cousins (Dr.)
Moroccan Pharmacovigilance Centre
Morocco
EU contribution
€ 151 886
Address
Rue Lamfedel Cherkaoui Madinat Al Irfane
10100 Rabat
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Rachida Soulaymani Bencheikh (Prof.)
KOBENHAVNS UNIVERSITET
Denmark
EU contribution
€ 110 731
Address
Norregade 10
1165 Kobenhavn
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ivan Kristoffersen (Mr.)
Elliot Brown Consulting
United Kingdom
EU contribution
€ 23 379
Address
Woodfall Avenue 7
EN5 2EZ Barnet, Herts
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Elliot Brown (Dr.)
The Zuellig Foundation, Inc.
Philippines
EU contribution
€ 18 376
Address
18-A Trafalgar Plaza/h.v. Dela Costa Str 105
1227 Makati City
Activity type
Other
Administrative Contact
Kenneth Hartigan-Go (Dr.)
UNIVERSITY OF GHANA
Ghana
EU contribution
€ 52 644
Address
.
N/A Legon Accra
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Alexander Nii Oto Dodoo (Dr.)
Pharmacy and Poisons Board, Ministry of Health
Kenya
EU contribution
€ 40 660
Address
Lenana Road 1
27663-0506 Nairobi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jayesh Manharlal Pandit (Dr.)